BeOne Medicines (NASDAQ:ONC) Stock Keeps “Buy” Rating at Truist Financial

BeOne Medicines (NASDAQ:ONC)‘s stock had its “buy” rating reaffirmed by analysts at Truist Financial in a research report issued on Friday, Benzinga reports. They presently have a $448.00 price objective on the stock, up from their previous price objective of $420.00. Truist Financial‘s price objective would indicate a potential upside of 9.80% from the stock’s previous close.

A number of other analysts have also issued reports on ONC. Guggenheim increased their price target on shares of BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a $470.00 price objective on shares of BeOne Medicines in a research report on Thursday. Nomura upped their price objective on shares of BeOne Medicines from $454.75 to $484.91 and gave the company a “buy” rating in a research note on Thursday, August 6th. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $450.00 to $459.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Finally, Wells Fargo & Company increased their target price on shares of BeOne Medicines from $400.00 to $435.00 and gave the stock an “overweight” rating in a research report on Friday. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, BeOne Medicines has a consensus rating of “Moderate Buy” and an average target price of $434.39.

BeOne Medicines Stock Up 5.4%

BeOne Medicines stock traded up $20.77 during mid-day trading on Friday, hitting $408.02. The company’s stock had a trading volume of 539,032 shares, compared to its average volume of 318,362. The firm’s 50 day moving average is $362.80 and its 200 day moving average is $325.98. The company has a market cap of $44.80 billion, a PE ratio of 71.90 and a beta of 0.63. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. BeOne Medicines has a 52-week low of $253.95 and a 52-week high of $409.80.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, November 5th. The company reported $3.64 EPS for the quarter, topping analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.76 billion. On average, analysts anticipate that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Buying and Selling at BeOne Medicines

In related news, COO Xiaobin Wu sold 280 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total transaction of $106,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Chan Lee sold 1,115 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $375.00, for a total value of $418,125.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 376,373 shares of company stock worth $134,848,154 in the last quarter. 6.19% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mather Group LLC. boosted its position in shares of BeOne Medicines by 192.0% during the 3rd quarter. Mather Group LLC. now owns 73 shares of the company’s stock valued at $27,000 after acquiring an additional 48 shares in the last quarter. GAMMA Investing LLC raised its position in BeOne Medicines by 39.5% in the third quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after purchasing an additional 34 shares in the last quarter. Parallel Advisors LLC raised its position in BeOne Medicines by 24.0% in the first quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after purchasing an additional 68 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in BeOne Medicines in the third quarter worth about $106,000. Finally, Knights of Columbus Asset Advisors LLC bought a new position in BeOne Medicines during the third quarter worth about $106,000. 48.55% of the stock is owned by institutional investors.

Trending Headlines about BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q3 results topped estimates and revenue guidance was raised. BeOne reported adjusted EPS of $3.64 versus the $2.34 consensus and revenue of $1.89 billion versus $1.76 billion expected. The company also raised its 2026 revenue guidance, signaling stronger business expectations. BeOne Q3 earnings and guidance
• Positive Sentiment: FDA granted priority review to a BRUKINSA combination. The review concerns use in first-line mantle cell lymphoma; a label expansion could broaden the drug’s potential market if approved. FDA priority review for BRUKINSA
• Positive Sentiment: Analysts raised their price targets and maintained positive ratings. Barclays lifted its target to $446 with an “overweight” rating; Citizens JMP raised its target to $463 and kept “market outperform”; Wells Fargo raised its target to $435 and retained “overweight.” The revisions reflect improved analyst expectations, though targets are not guarantees of future performance. Barclays rating information Citizens JMP rating information Wells Fargo rating information

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.